Corneal Implants Market Report 2025

The corneal implants market size has grown strongly in recent years. It will grow from $1.34 billion in 2024 to $1.43 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to pioneering surgical techniques, early biomaterial innovation, emergence of keratoplasty, rising awareness of eye disorders, pioneering surgeons' contributions.

The corneal implants market size is expected to see strong growth in the next few years. It will grow to $1.9 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to personalized medicine approaches, greater accessibility and awareness, innovative biomaterials development, rise in refractive surgeries, growing aging population. Major trends in the forecast period include emergence of minimally invasive techniques, regulatory support and approvals, increased awareness and accessibility, innovation in biomaterials, rise in refractive surgery.

The anticipated rise in the prevalence of corneal disorders is poised to drive the expansion of the corneal implant market in the coming years. Corneal disorders encompass a range of medical conditions affecting the cornea, the clear, dome-shaped front surface of the eye, leading to visual impairment and discomfort. The growing incidence of corneal disorders has resulted in an increased demand for corneal implants, offering diverse solutions for treating corneal abnormalities, enhancing corneal integrity, alleviating symptoms, and improving vision. As an example, data from the Center for Disease Control (CDC) in December 2022 revealed that in the United States, the prevalence of cataracts (a corneal disorder) among individuals aged over 40 is estimated at 20.5 million, constituting approximately 17.2% of the population in that age group. Moreover, this figure is projected to surpass 30 million by the year 2028. Consequently, the upsurge in corneal disorders is a key driver for the growth of the corneal implant market.

The escalating healthcare expenditure is also expected to propel the expansion of the corneal implants market in the foreseeable future. Healthcare expenditure denotes the total resources, including financial resources, allocated to healthcare goods and services within a specific period and geographical area. The increased investment in healthcare facilitates the adoption of advanced technologies and surgical techniques within the ophthalmology field, including the utilization of corneal implants. For instance, as per the 2021-2030 National Health Expenditure (NHE) report released by the Centers for Medicare & Medicaid Services in March 2022, the projected growth suggests an average annual increase of 5.1% in national health spending between 2021 and 2030, reaching a total of nearly $6.8 trillion. Furthermore, it is anticipated that from 2021 to 2030, Medicare spending will rise at a 7.2% annual pace, while Medicaid spending will increase at a 5.6% annual rate. Hence, the escalating healthcare expenditure is a significant factor propelling the growth of the corneal implants market.

Major companies in the corneal implants market are concentrating on developing innovative corneal contouring solutions to enhance vision correction and treat various corneal disorders. These solutions involve advanced surgical techniques and devices aimed at reshaping the cornea to improve vision and address refractive errors or corneal diseases. For instance, in June 2024, CorneaGen, a US-based developer of medical devices focused on eliminating corneal blindness, launched the Corneal Tissue Addition for Keratoplasty (CTAK). This innovative solution offers a highly effective approach to corneal contouring for keratoconic eyes. The CTAK technique involves adding donor corneal tissue to the existing cornea instead of completely replacing it. This method aims to restore the natural contour of the cornea, thereby enhancing optical clarity and improving overall visual outcomes for patients.

Major players in the corneal implants market are embracing strategic partnerships to advance and introduce tissue-derived implants for ophthalmological applications. Strategic partnerships involve companies leveraging each other's strengths and resources for mutual benefit and success. For instance, in July 2022, Carl Zeiss Meditec AG, a German medical technology company, collaborated with Precise Bio, a US regenerative medicine company, focusing on the development and market launch of engineered corneal tissue for transplants. This initiative specifically caters to patients in need of endothelial keratoplasty and natural lenticule transplants for conditions such as keratoconus and vision correction. The partnership leverages ZEISS' global leadership in ophthalmology and Precise's innovative 4D bio-fabrication platform technology.

In January 2023, Viatris Inc., a US-based pharmaceutical and healthcare corporation, completed the acquisitions of Oyster Point Pharma and Family Life Sciences for $415 million and $280 million, respectively. Through these acquisitions, Viatris Inc. aims to expand its commercial presence and portfolio, positioning itself as a global leader in eye care, and addressing the unmet needs of patients with ophthalmic diseases and eye care professionals. Oyster Point Pharma, a US biopharmaceutical company, specializes in identifying, developing, and marketing novel treatments for eye diseases, while Family Life Sciences, an Indian drug development platform, specializes in ophthalmology.

Major companies operating in the corneal implants market include Florida Lions Eye Bank Inc., Alcon Inc., Aurolab Aravind Eye Care System, CorneaGen, AJL Ophthalmic SA, DIOPTEX Co. Ltd., KeraMed Inc., Alabama Eye Bank Inc., CorNeat Vision Ltd., MediPhacos, EyeYon Medical Ltd., Linkocare Life Sciences AB, Price Vision Group, Cornea Biosciences LLC, Massachusetts Eye and Ear Infirmary, Carl Zeiss Meditec AG, Precise Bio Inc., Bausch & Lomb Incorporated, Johnson & Johnson Vision, Abbott Medical Optics Inc., STAAR Surgical Company, ZEISS Group, Hoya Corporation, Rayner Intraocular Lenses Limited, HumanOptics AG, Morcher GmbH, Lenstec Inc., Ocular Systems Inc., Moria SA, DORC International BV, Coroneo Pty Ltd, FCI Ophthalmics Inc.

North America was the largest region in the cornea implants market in 2024. Asia Pacific is expected to be the fastest-growing region in the global cornea implants market during the forecast period. The regions covered in the corneal implants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the corneal implants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Corneal implants involve a surgical intervention aimed at either replacing or enhancing a damaged or diseased cornea through the integration of an artificial or prosthetic device. This procedure is carried out to address visual impairments and alleviate associated pain.

The two primary categories of corneal implants are artificial corneal implants and human corneal implants. Artificial corneal implants are medical devices specifically designed to substitute a damaged or diseased cornea. Various techniques, such as endothelial keratoplasty and penetrating keratoplasty, are employed for corneal implants. These procedures serve diverse applications, including addressing conditions such as keratoconus, Fuchs dystrophy, infectious keratitis, corneal ulcers, among others. The implementation of corneal implant procedures typically takes place in medical facilities such as hospitals and ophthalmic centers.

The corneal implants market research report is one of a series of new reports that provides corneal implants market statistics, including corneal implants industry global market size, regional shares, competitors with a corneal implants market share, detailed corneal implants market segments, market trends and opportunities, and any further data you may need to thrive in the corneal implants industry. This corneal implant market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The corneal implants market includes revenues earned by entities by providing corneal implantation services, including deep anterior lamellar keratoplasty (DALK) and Descemet rhexis without endothelial keratoplasty (DWEK). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.